Healthcare
China cancer diagnosis player ChosenMed gets Series B
ChosenMed, a Beijing-based tumor detection company has raised a Series B round of more than RMB100 million ($14 million) led by state-owned Shanghai Lianhe Investment.
Chinese drug developer Mabworks raises $159m Series C
Beijing Mabworks Biotech has raised a RMB1.13 billion ($159 million) Series C round led by CICC Capital, Lyzz Capital, CITIC Securities Investment, and Huge Capital.
Carlyle achieves partial exit in India’s Metropolis Healthcare
The Carlyle Group has sold 6.5 million shares of Metropolis Healthcare for INR7.5 billion ($98.7 million) to exit nearly its entire position in the Indian medical diagnostics chain.
Qiming defies coronavirus to close seventh China fund at $1.1b
Qiming Venture Partners has closed its seventh US dollar-denominated China fund at $1.1 billion following an approximately two-month process that involved a last-minute relocation of on-site due diligence from Shanghai to San Francisco.
CICC, GL Ventures join $66m round for Suzhou Ribo Life Science
Chinese drug developer Suzhou Ribo Life Science has raised RMB470 million ($66 million) in an extended Series C round led by China State-owned Capital Venture Capital Fund, CICC Capital and GL Ventures, the VC arm of Hillhouse Capital.
HighLight-backed Zentalis raises $165m in US IPO
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.
LeapFrog leads $55m round for India's MedGenome
MedGenome, an India-focused provider of genetic testing solutions, has raised $55 million in a funding round led by LeapFrog Investments.
Square Peg joins Series B for Singapore's Doctor Anywhere
Australian VC firm Square Peg Capital has joined a $27 million Series B round for Singapore-based healthcare technology provider Doctor Anywhere.
Shanghai CDMO player gets $51m Series A
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $51 million in Series A funding led by Lyfe Capital.
BGH, OTPP pull out of New Zealand dentistry deal
BGH Capital and Ontario Teachers’ Pension Plan (OTPP) have scrapped plans to acquire New Zealand dentistry chain Abano Healthcare citing material changes caused by COVID-19.
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
GP profile: GTJA Investment Group
Having established itself as a leading player in the renminbi space, China healthcare sector specialist GTJA Investment Group now wants to prove its worth to overseas LPs
Hillhouse leads $60m Series B for China biotech player
Hillhouse Capital has led a $60 million Series B round for China’s Iaso Biotherapeutics via its newly established VC unit GL Ventures.
PE-backed InnoCare raises $288m in Hong Kong IPO
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
Partners Group rebuffed in pursuit of Australia's Healius
Australian healthcare services provider Healius has rejected a A$2.1 billion ($1.4 billion) buyout offer from Partners Group, saying it doesn’t reflect the fundamental value of the company.
China's Harbour BioMed gets $75m Series B extension
China-based biotech developer Harbour BioMed has closed an extended Series B round with a fresh $75 million commitment from a group of VCs. It initially raised $85 million in 2018.
Fund focus: Quadria's health check
Having raised $595 million for its second healthcare fund, Singapore-headquartered Quadria Capital has a bulky war-chest for investments in fast-growing companies in India and Southeast Asia
Deal focus: UTEC positions Tricog for Japan expansion
University of Tokyo Edge Capital built an unusual bridge between the start-up worlds of Japan and India when backed Tricog's artificial intelligence-enabled healthcare solution
Korea's SK Telecom launches digital healthcare JV with local GP
Korea’s SK Telecom has spun out its digital healthcare development unit to form a joint venture (JV) with local private equity firm Newlake Alliance Management.
OrbiMed targets $750m for Asia healthcare fund
US-based healthcare investment firm OrbiMed has launched its fourth Asian private equity fund with a view to raising $750 million.
China’s GenFleet Therapeutics raises $50m Series B
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
Motilal Oswal invests $32m in Indian TB diagnostic player
Motilal Oswal Private Equity (MOPE) has committed INR2.4 billion ($32.4 million) to Molbio Diagnostics, a molecular diagnostics manufacturer that specializes in low-cost diagnosis of tuberculosis and other diseases.
Singapore's Quadria closes second healthcare fund at $595m
Quadria Capital, a Singapore-headquartered private equity firm that invests in healthcare companies across India and Southeast Asia, has raised $595 million for its second fund.